Allogeneic DCG promote lung NK cell activation and antitumor effect after invariant NKT cell activation

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3411-3417

  Hasegawa, Hiroshi ^a   Yamashita, Kimihiro ^a   Otubo, Dai ^a   Fujii, Shin Ichiro ^b   Kamigaki, Takashi ^a   Kuroda, Daisuke ^a   Kakeji, Yoshihiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b RIKEN Center for Integrative Medical Sciences   (Japan)

Author keywords

Allogeneic cells; Dendritic cells; NK cells; NKT cells; Tumor immunity

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; GAMMA INTERFERON;

ALLOGENEIC DENDRITIC CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG PULSE THERAPY; FEMALE; LUNG; LUNG METASTASIS; LUNG TUMOR; MELANOMA B16; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; SPLEEN; TUMOR MODEL; ALLOGENEIC CELLS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; COLON TUMOR; DRUG EFFECT; EXPERIMENTAL MAMMARY NEOPLASM; EXPERIMENTAL MELANOMA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METASTASIS; NK CELLS; TUMOR IMMUNITY;

ALLOGENEIC CELLS; DENDRITIC CELLS; NK CELLS; NKT CELLS; TUMOR IMMUNITY;

ANIMALS; COLONIC NEOPLASMS; FEMALE; GALACTOSYLCERAMIDES; INTERFERON-GAMMA; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NATURAL KILLER T-CELLS;

EID: 84906309004     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Cerundolo V, Silk JD, Masri SH and Salio M: Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 9: 28-38, 2009.
2. Godfrey DI and Rossjohn J: New ways to turn on NKT cells. J Exp Med 208: 1121-1125, 2011.
3. Morita M, Motoki K, Akimoto K, Natori T, Sakai T, Sawa E, Yamaji K, Koezuka Y, Kobayashi E and Fukushima H Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 38: 2176-2187, 1995.
4. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, Kondo E, Harada M, Koseki H, Nakayama T, Tanaka Y and Taniguch M: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc Natl Acad Sci USA 95: 5690-5693, 1998.
5. Chiodoni C, Stoppacciaro A, Sangaletti S, Gri G, Cappetti B, Koezuka Y and Colombo MP: Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases. Eur J Immunol 31: 3101-3110, 2001.
6. Fujii S, Shimizu K, Kronenberg M and Steinman RM: Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat immunol 3: 867-874, 2002.
7. Yasuda T, Kamigaki T, Kawasaki K, Nakamura T, Yamamoto M, Kanemitsu K, Takase S, Kuroda D, Kim Y, Ajiki T and Kuroda Y: Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother 56: 1025-1036, 2007.
8. Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA and Okada H: Premetastatic soli and prevention of breast cancer brain metastasis. Neuro Oncol 15: 891-903, 2013.
9. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H and Pinedo HM: A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8: 3702-3709, 2002.
10. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson A, Geller M, Liu N, Annable R, Shay J, Kirchhoff K, Nishi N, Ando Y, Hayashi K, Hassoun H, Steinman RM and Dhodapkar MV: Sustained expansion of NKT cells and antigen-specific T-cells after injection of alpha-galactosylceramide loaded mature dendritic cells in cancer patients. J Exp Med 201: 1503-1517, 2005.
11. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383-389, 2004.
12. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M and Fujisawa T: A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11: 1910-1917, 2005.
13. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T and Nakayama T: A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182: 2492-2501, 2009.
14. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, Clerici M, Greco M and Villa ML: Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89: 1463-1472, 2003.
15. Sakakura K, Chikamatsu K, Takahashi K, Whiteside TL and Furuya N: Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 55: 151-159, 2006.